Literature DB >> 15932751

Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio.

Masae Kokubun1, Yuji Imafuku, Minoru Okada, Yoshito Ohguchi, Tatsuhiko Ashikawa, Toshiyuki Yamada, Hiroshi Yoshida.   

Abstract

BACKGROUND: C reactive protein (CRP) and serum amyloid A (SAA) are similarly sensitive indicators of inflammation, but discrepancies are recognized in several disease conditions. SAA levels are generally higher and vary more among individuals. The significance of the SAA/CRP ratio was evaluated in the estimation of SAA.
METHODS: Sera of out-patients with rheumatoid arthritis (RA) and healthy subjects were measured for CRP and SAA cross-sectionally and longitudinally by a highly sensitive latex agglutination turbidimetric immunoassay. The results were classified into four groups according to the CRP concentration, and the SAA/CRP ratios were calculated and evaluated.
RESULTS: In the cross-sectional study, CRP and SAA were shown to correlate significantly in sera of patients with RA, but not in healthy subjects. The SAA/CRP ratios were wide RA patients and tended to decrease in the range and mean values were observed depending on the concentration of CRP. In the longitudinal study, variations of the ratio among individuals were wide, but smaller and similar within individuals. The difference in magnitude of the ratios is due to the difference in SAA concentration.
CONCLUSION: Variations of SAA/CRP ratios were affected by SAA concentrations. The ratio should be checked in the evaluation of SAA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15932751     DOI: 10.1016/j.cccn.2005.04.006

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  9 in total

Review 1.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases.

Authors:  Nishkantha Arulkumaran; Robert J Unwin; Frederick Wk Tam
Journal:  Expert Opin Investig Drugs       Date:  2011-04-21       Impact factor: 6.206

2.  Serum Amyloid A as a Biomarker for Radiation Exposure.

Authors:  Mary Sproull; Tamalee Kramp; Anita Tandle; Uma Shankavaram; Kevin Camphausen
Journal:  Radiat Res       Date:  2015-06-26       Impact factor: 2.841

3.  Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling.

Authors:  Chibo Liu; Chunqin Pan; Jianmin Shen; Haibao Wang; Liang Yong
Journal:  Oncol Lett       Date:  2012-03-30       Impact factor: 2.967

4.  Characterizing Patients with Recurrent Urinary Tract Infections in Vesicoureteral Reflux: A Pilot Study of the Urinary Proteome.

Authors:  Dijana Vitko; Patricia S Cho; Stephen A Kostel; Shannon E DiMartino; Lily D Cabour; Matthew A Migliozzi; Tanya Logvinenko; Peter G Warren; John W Froehlich; Richard S Lee
Journal:  Mol Cell Proteomics       Date:  2020-01-02       Impact factor: 5.911

5.  Validity of serum amyloid A and HMGB1 as biomarkers for early diagnosis of gastric cancer.

Authors:  Ali A Ghweil; Heba A Osman; Mohammed H Hassan; Abeer Mm Sabry; Reem E Mahdy; Ahmed Rh Ahmed; Ahmed Okasha; Ashraf Khodeary; Hesham H Ameen
Journal:  Cancer Manag Res       Date:  2020-01-08       Impact factor: 3.989

6.  Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis.

Authors:  Mahmood M T M Ally; Bridget Hodkinson; Pieter W A Meyer; Eustasius Musenge; Mohammed Tikly; Ronald Anderson
Journal:  Mediators Inflamm       Date:  2013-04-07       Impact factor: 4.711

7.  VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.

Authors:  J L Kuiper; J S W Lind; H J M Groen; J Roder; J Grigorieva; H Roder; A M C Dingemans; E F Smit
Journal:  Br J Cancer       Date:  2012-10-18       Impact factor: 7.640

8.  Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy.

Authors:  Christoph Stettler; Nicholas Witt; Robyn J Tapp; Simon Thom; Sabin Allemann; Therese Tillin; Alice Stanton; Eoin O'Brien; Neil Poulter; J Ruth Gallimore; Alun D Hughes; Nish Chaturvedi
Journal:  Diabetes Care       Date:  2009-02-24       Impact factor: 19.112

9.  Polymorphisms in the selenoprotein S gene: lack of association with autoimmune inflammatory diseases.

Authors:  Alfonso Martínez; Jose Luis Santiago; Jezabel Varadé; Ana Márquez; José Ramón Lamas; Juan Luis Mendoza; Hermenegildo de la Calle; Manuel Díaz-Rubio; Emilio G de la Concha; Benjamín Fernández-Gutiérrez; Elena Urcelay
Journal:  BMC Genomics       Date:  2008-07-14       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.